EarningsQ2 2025 Earnings Report

ANGLE plc (DWV) Q2 2025 Earnings Report

0 Followers

Previous Report: Q4 2024

Next Report: Q4 2025

DE:DWV Q2 2025 EPS Results

Actual EPS-€0.03

Consensus EPS―

Beat/Miss―

One Year Ago EPS-€0.03

DE:DWV Q2 2025 Revenue Results

Actual Revenue€939.81K

Expected Revenue€713.86K

Beat/MissBeat by +€225.95K

YoY Revenue Growth-23.02%

Earnings Announcement Details

QuarterQ2 2025

Date09/09/2025

TimeBefore Open

Conference CallTuesday, September 9, 2025

DE:DWV Upcoming Earnings

ANGLE plc's next earnings date is estimated for April 29, 2027, based on past reporting schedules.

Q2 2025 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2025 Earnings Call Summary

Q2 2025

Earnings Call Date:Sep 09, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.

Company Guidance

During the ANGLE 2025 Interim Results Call, CEO Andrew Newland provided comprehensive guidance on the company's financial and operational progress for the first half of the fiscal year. Despite facing adverse market conditions that pressured revenue, with pharma revenue down and product revenue flat compared to the prior year, ANGLE has made significant strides in commercialization and development. Key achievements include the completion of three major pharma projects with Eisai and AstraZeneca, the development of the DNA dual analysis using Illumina's NGS assay, and the commencement of a collaboration with Myriad Genetics for large-scale commercialization of the Parsortix system. The company has maintained tight cost control, reducing operating expenditure by 12%, and holds a cash position of GBP 6.6 million, with a runway extending into Q1 2026. Despite the challenging environment, ANGLE anticipates further developments with multiple large pharma and med tech companies and is actively pursuing additional funding sources to ensure continued growth and innovation in its cancer diagnostic solutions.

Successful Completion of Large Pharma Projects

ANGLE successfully completed three large pharma projects with Eisai and AstraZeneca, demonstrating the utility of the Parsortix system in HER2 breast cancer trials and developing assays for DNA Damage Response and Androgen Receptor.

MedTech Collaboration with Myriad Genetics

ANGLE announced its first large medtech collaboration with Myriad Genetics, offering potential for large-scale commercialization of the Parsortix system.

Development of DNA Dual Analysis

A major achievement was the development of the DNA dual analysis, Illumina, end-to-end NGS assay, which identifies twice as many mutations as ctDNA alone.

Accreditation Progress for Clinical Lab

ANGLE is making good progress on accrediting its clinical lab, targeting completion by the end of the year, which would enable offering tests directly for patient management.

DE:DWV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Apr 29, 2027	2026 (Q4)	- / -	-0.011	―
Sep 24, 2026	2026 (Q2)	- / >-0.01	-0.034	93.10% (+0.03)
Jun 22, 2026	2025 (Q4)	-0.02 / -0.03	-0.024	-30.00% (>-0.01)
Sep 09, 2025	2025 (Q2)	- / -0.03	-0.034	0.00% (0.00)
May 28, 2025	2024 (Q4)	- / -0.02	-0.047	50.00% (+0.02)
Sep 26, 2024	2024 (Q2)	- / -0.03	-0.045	23.68% (+0.01)
Jun 05, 2024	2023 (Q4)	- / -0.05	-0.058	18.37% (+0.01)
Sep 07, 2023	2023 (Q2)	- / -0.04	-0.046	2.56% (<+0.01)
Apr 21, 2023	2022 (Q4)	- / -0.06	-0.037	-58.06% (-0.02)
Sep 29, 2022	2022 (Q2)	- / -0.05	-0.043	-8.33% (>-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed